Age-dependent levels of plasma neuropeptides in normal children

Regulatory Peptides

Volumn 109, Issue 1-3, 2002, Pages 189-192

  O'Dorisio, M Sue ^a,c   Hauger, Marsha ^b   O'Dorisio, Thomas M ^a  

^a UNIVERSITY OF IOWA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Children; GRP; IGF 1; Neuropeptides; NPY; Octreotide; Pancreastatin; Somatostatin; Substance P; VIP

Indexed keywords

GASTRIN RELEASING PEPTIDE; NEUROPEPTIDE; NEUROPEPTIDE Y; OCTREOTIDE; PANCREASTATIN; PLASMA PROTEIN; SOMATOMEDIN C; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SUBSTANCE P; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; INFANT; NEUROBLASTOMA; PRIORITY JOURNAL; PUBLICATION; RADIOIMMUNOASSAY; UMBILICAL CORD BLOOD;

ADOLESCENT; ADULT; AGING; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; INFORMED CONSENT; INSULIN-LIKE GROWTH FACTOR I; NEUROPEPTIDES; RADIOIMMUNOASSAY;

EID: 0037111163     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(02)00203-3     Document Type: Article

References (26)

1. Brodeur G.M., Castleberry R.P. Neuroblastoma. 1997;761-797.
2. Anderson D.J. Molecular control of cell fate in the neural crest: the sympathoadrenal lineage. Annu. Rev. Neurosci. 16:1993;129-158.
3. Anderson D.J., Axel R. A bipotential neuroendocrine precursor whose choice of cell fate is determined by NGF and glucocorticoids. Cell. 47:1986;1079-1090.
4. O'Dorisio M.S., Fleshman D.J., Qualman S.J., O'Dorisio T.M. Vasoactive intestinal peptide: autocrine growth factor in neuroblastoma. Regul. Pept. 37:1992;213-226.
5. Hoshino M., Yanaihara C., Ogino K., Iguchi K., Sato H., Suzuki T.et al. Production of VIP-and PHM (human PHI)-related peptides in human neuroblastoma cells. Peptides. 5:1984;155-160.
6. Scheibel E., Rechnitzer C., Fahrenkrug J., Hertz H. Vasoactive intestinal polypeptide (VIP) in children with neural crest tumours. Acta Paediatr. Scand. 71:1982;721-725.
7. Yagihashi S., Shimoyama N., Morita T., Sato T., Yanaihara N. Ganglioneuroblastoma containing several kinds of neuronal peptides with watery diarrhea syndrome. Acta Pathol. Jpn. 32:1982;807-814.
8. Tyrrell S., Landis S.C. The appearance of NPY and VIP in sympathetic neuroblasts and subsequent alterations in their expression. J. Neurosci. 14:1994;4529-4547.
9. Muller J.M., Lolait S.J.Y.V.C., Sadee W., Waschek J.A. Functional vasoactive intestinal polypeptide (VIP) receptors in human neuroblastoma subclones that contain VIP precursor mRNA and release VIP-like substances. J. Biol. Chem. 264:1989;3647-3650. [abstr].
10. Rascher W., Kremens B., Wagner S., Feth F., Hunneman D.H., Lang R.E. Serial measurements of neuropeptide Y in plasma for monitoring neuroblastoma in children. J. Pediatr. 122:1993;914-916.
11. Fruhwald M.C., O'Dorisio M.S., Cottingham S.L., Qualman S.J., O'Dorisio T.M. Neuropeptides in developmental tumors of the central and peripheral nervous system. Ann. N. Y. Acad. Sci. 865:1998;420-426.
12. Olasmaa M., Pahlman S., Terenius L. Beta-adrenoceptor, vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) receptors functionally coupled to adenylate cyclase in the human neuroblastoma SK-N-MC cell line. Neurosci. Lett. 83:1987;161-166.
13. Hayashi Y., Ohi R., Sone M., Takahashi K., Mouri T., Watanabe T.et al. Significance of plasma neuropeptide Y (NPY) in diagnosis and prognosis of neuroblastoma. Prog. Clin. Biol. Res. 366:1991;359-365.
14. Clark C.E. Re: secretin and autism: a two-part clinical investigation. J. Autism Dev. Disord. 31:2001;248-249.
15. Bona G., Aquili C., Ravanini P., Gallina M.R., Cigolotti A.C., Zaffaroni M.et al. Growth hormone, insulin-like growth factor-I and somatostatin in human fetus, newborn, mother plasma and amniotic fluid. Panminerva Med. 36:1994;5-12.
16. Mitchell M.L., Hermos R.J., Schoepfer A., Orson J.M. Reference ranges for insulin-like growth factor-1 in healthy children and adolescents, determined with filter-paper blood specimens. Clin. Chem. 36:1990;2138-2139.
17. Morris A.H., Joyce J.L., Reiter E.O. Increased insulin-like growth factor I binding to red blood cells of normal prepubertal children. Pediatr. Res. 25:1989;409-413.
18. Juul A., Bang P., Hertel N.T., Main K., Dalgaard P., Jorgensen K.et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J. Clin. Endocrinol. Metab. 78:1994;744-752.
19. Qualman S.J., O'Dorisio M.S., Fleshman D.J., Shimada H., O'Dorisio T.M. Neuroblastoma. Correlation of neuropeptide expression in tumor tissue with other prognostic factors. Cancer. 70:1992;2005-2012.
20. Piper P.J., Said S.I., Vane J.R. Effects on smooth muscle preparations of unidentified vasoactive peptides from intestine and lung. Nature. 225:1970;1144-1146.
21. O'Dorisio T.M., Mekhjian H.S., Ellison E.C., O'Dorisio M.S., Gaginella T.S., Woltering E.A. Role of peptide radioimmunoassay in understanding peptide-peptide interactions and clinical expression of gastroenteropancreatic endocrine tumors. Am. J. Med. 82:1987;60-67.
22. Desai D.C., O'Dorisio T.M., Schirmer W.J., Jung S.S., Khabiri H., Villanueva V.et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul. Pept. 96:2001;113-117.
23. Maton P.N., O'Dorisio T.M., Howe B.A., McArthur K.E., Howard J.M., Cherner J.A.et al. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N. Engl. J. Med. 312:1985;17-21.
24. Weiss D.W., Hirt R., Tarcic N., Berzon Y., Ben Zur H., Breznitz S.et al. Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Behav. Med. 22:1996;5-14.
25. Winther J.E., Espersen K., Kanstrup I.L., Christensen N.J. Age-related changes of exercise-induced plasma catecholamines and neuropeptide Y responses in normal human subjects. Acta Physiol. Scand. 144:1992;129-133.
26. Glaser B., Landaw H. Long-term treatment with the somatostatin analogue SMS 201-995: alternative to pancreatectomy in persistent hyperinsulinaemic hypoglycaemia of infancy. Digestion. 45(Suppl. 1):1990;27-35.